Michael Baltezor

Michael Baltezor, Ph.D., is CritiTech’s Chief Scientific Officer. He provides leadership to our scientific and technical teams regarding all areas of drug development from POC through commercial manufacturing. He also provides hands-on assistance to our clients.

For 35 years before Dr. Baltezor joined CritiTech in 2014, he spent his career in the pharmaceutical industry where he developed deep expertise in pharmaceutical chemistry and product development, analytical chemistry, toxicology, pharmacology, formulation, drug delivery, CMC, regulatory documentation, cGMP, Phase II and commercial production, quality operations and FDA audits. He has held numerous key leadership positions with Sandoz, Marion Labs, Quintiles, Aptuit, Medi-Flex and Cardinal Health.

Dr. Baltezor has been involved with the development of over 20 drugs that have been approved by the FDA. He is the co-inventor of Cardizem CD, which generates over $2B in annual sales.

Dr. Baltezor earned his Ph.D. and M.S. in Pharmaceutics and Pharmaceutical Chemistry from the University of Kansas, as well as his B.S. in Chemistry from Missouri Western State University. He likes reading scientific journals, working on home projects and spending time with his family.